Literature DB >> 1909228

Outcome of a ceftriaxone/cefotaxime interchange programme in a major teaching hospital.

A Gutensohn1, D Bunz, L Frighetto, P Jewesson.   

Abstract

A two-stage intervention programme was performed to enable the effective substitution of ceftriaxone for cefotaxime in a teaching hospital with large numbers of transient prescribers. One hundred and sixteen patients with a variety of bacterial infections were randomized to an open, historical control comparative study to determine if ceftriaxone was an acceptable replacement for cefotaxime. For 6 months prior to the intervention, both cephalosporins were available on formulary. Following an initial informational stage, a therapeutic interchange programme was implemented to convert prescriptions for cefotaxime to ceftriaxone. Ceftriaxone and cefotaxime were equivalent in terms of microbiological and clinical efficacy and patient tolerance in 77 evaluable patients. No changes in prescriber service occurred after the changeover. Post-intervention treatment courses required a ceftriaxone/cefotaxime interchange in 28% of the cases. Ceftriaxone appeared to be a suitable and cost-effective alternative to cefotaxime in this hospital. The intervention programme successfully invoked the formulary change with minimal expense and prescriber opposition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909228     DOI: 10.1159/000238928

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  Cost-effectiveness and value of an IV switch.

Authors:  P Jewesson
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

2.  Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections.

Authors:  S Segev; R Raz; E Rubinstein; H Shmuely; D Hassin; N Rosen; E Platau; S Ben Assuli; S Pitlik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 4.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

5.  Comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program.

Authors:  S Martinusen; D Chen; L Frighetto; D Bunz; H G Stiver; P J Jewesson
Journal:  CMAJ       Date:  1993-04-01       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.